Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Companies also Announce Phase 1/2 Clinical Trial Evaluating SB-525 in Adults with Severe Hemophilia A is Now Open for Enrollment RICHMOND, Calif., June 7, 2017 -- (Healthcare Sales & Marketing Network) -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) and P... Biopharmaceuticals, Regulatory Sangamo Therapeutics, Pfizer, Hemophilia, Gene Therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news